イベルメクチンってどうよ？Part. 30

[過去ﾛｸﾞ] イベルメクチンってどうよ？Part. 30 (1002ﾚｽ)
上下前次 1-新
通常表示 512ﾊﾞｲﾄ分割ﾚｽ栞

このｽﾚｯﾄﾞは過去ﾛｸﾞ倉庫に格納されています｡
次ｽﾚ検索歴削→次ｽﾚ栞削→次ｽﾚ過去ﾛｸﾞﾒﾆｭｰ

570: 名無しのアビガン(東京都) (ﾜｯﾁｮｲW 8b58-2iIz) [] 2022/03/24(木) 14:33:32.87 ID:DMT/l38K0

>>559
低学歴だから論文読めないのなw
哀れすぎるwwww

https://www.mdpi.com/2076-393X/9/8/848/htm

The mechanism of action of an mRNA vaccine is very similar to the mechanism of viral infection. By means of the translational machinery of the host cells, the mRNA is translated into proteins. These proteins may undergo post-translational modification and either function within the cell or be secreted. Proteasomes degrade cytoplasmic proteins, thus generating antigenic peptide epitopes that are transported to the ER and loaded onto MHC class I molecules (Figure 2).

https://www.mdpi.com/vaccines/vaccines-09-00848/article_deploy/html/images/vaccines-09-00848-g002.png

MHC class I can present these peptides on the surface of the cell for specific CD8+ T cells. Alternatively, the secreted exogenous proteins can be taken up by professional antigen-presenting cells, either residing in the tissue or draining lymph nodes, and then be processed and presented in MHC class II [17]. In mRNA-vaccinated individuals (BNT162b1), T-cells can be detected to be secreting interferon-γ upon in vitro restimulation with SARS-CoV-2 peptides, which confirms the induction of CD4+ Th-cells through MHC class II [39]. Professional antigen-presenting cells also can present exogenous antigens, which are processed via alternative intracellular routing and presented via MHC class I (cross-presentation) [54,55].

http://krsw.5ch.net/test/read.cgi/covid19/1647768960/570

上下前次 1-新書関写板覧索設栞歴

あと 422 ﾚｽあります
ｽﾚ情報赤ﾚｽ抽出画像ﾚｽ抽出歴の未読ｽﾚ AAｻﾑﾈｲﾙ

ぬこの手ぬこTOP 0.014s